EvidentMedsEvidentMeds
Estrogen / Sex HormoneNot Controlled Black Box Warning

Vivelle-Dot® / Climara® / Estrace®

Estradiol (17β-Estradiol)

Bayer (Climara) / Various Generic·FDA 1976 (oral) / 1986 (transdermal patch)·
0.025 mg/day patch0.05 mg/day patch0.075 mg/day patch0.1 mg/day patch0.5 mg oral1 mg oral2 mg oral0.25 mg/day gel0.5 mg/day gel0.1 mg vaginal tablet/insert

Version 2025-04 · Last reviewed April 1, 2025 · Methodology

List Price

$120

With Insurance

$10-30

Is your doctor receiving payments from drug companies?

Generic — no brand manufacturer. Search your doctor on CMS Open Payments →

FDA Black Box Warning

CARDIOVASCULAR DISORDERS, BREAST CANCER & ENDOMETRIAL CANCER

Estrogens increase the risk of endometrial cancer in women with an intact uterus (requires concurrent progestogen). Evidence on breast cancer and cardiovascular risk is complex — oral estrogens carry higher clot risk than transdermal. Baseline risk profile, timing of initiation, and formulation all influence individual risk.

Strict Contraindications

Undiagnosed abnormal vaginal bleedingKnown or suspected breast cancerHistory of estrogen-dependent cancerActive or recent blood clot (DVT/PE)Active liver diseaseKnown hypersensitivity

How It Works

Estradiol (17β-estradiol) is the primary and most potent form of estrogen produced by the human body. It acts by binding to estrogen receptors alpha and beta (ERα and ERβ), which are expressed in nearly every tissue — including the brain, heart, bones, breasts, uterus, skin, and blood vessels. Once bound, the estrogen-receptor complex travels to the cell nucleus and directly regulates gene expression, producing effects across many organ systems simultaneously.

ActivatesEstrogen receptors in the hypothalamus
Regulates the thermoregulatory center — reducing vasomotor symptoms (hot flashes, night sweats). The KNDy neuron pathway modulates body temperature; estradiol stabilizes this signaling.
ActivatesEstrogen receptors in bone (osteoblasts/osteoclasts)
Promotes bone formation and suppresses bone resorption — estradiol loss at menopause is the primary driver of rapid bone density decline in the first 5-10 years post-menopause.
ActivatesEstrogen receptors in the cardiovascular system
Maintains arterial flexibility, supports favorable lipid profiles (raises HDL, lowers LDL), and reduces atherosclerotic progression — effects that appear to diminish when estradiol is initiated long after menopause.
ActivatesEstrogen receptors in the brain
Supports serotonergic and cholinergic signaling, mood regulation, and possibly cognitive function. Estradiol withdrawal at menopause is associated with mood changes, cognitive fog, and sleep disruption.
ActivatesGenitourinary tissues
Maintains vaginal mucosa moisture, thickness, and pH; supports bladder and urethral tissue integrity — preventing genitourinary syndrome of menopause.

Why the side effects happen

Estradiol's wide receptor distribution explains both its benefits and its side effects. Breast tissue has abundant estrogen receptors — explaining breast tenderness and the long-term breast cancer risk requiring individualized monitoring. The liver's first-pass metabolism of oral estradiol generates prothrombotic clotting factors — the primary reason transdermal estradiol (patch, gel) is now preferred, as it bypasses the liver's first-pass metabolism and carries substantially lower clot risk than oral forms.

When Will I Feel It?

Vasomotor symptom relief (hot flashes) begins within days to weeks. Genitourinary changes take longer. Bone protective effects accumulate over months to years.

1
Days 1–14First two weeks

Vasomotor symptoms often improve noticeably within 1-2 weeks. Some women experience initial breast tenderness and bloating as estrogen levels rise.

2
Weeks 2–8Weeks 2-8

Mood, sleep, and cognitive symptoms generally improve. Genitourinary tissue begins responding — full restoration of vaginal tissue takes 3-6 months.

3
Month 3–63-6 months

Most systemic benefits established. Bone protective effects begin; full bone density support accumulates over 1-2 years. Dose adjustments are common at this stage.

4
Year 1+Ongoing

Continued bone density support, cardiovascular metabolic benefits (with early initiation), and sustained symptom control. Annual reassessment recommended.

Adherence Note

Patch consistency matters — changing the patch on a consistent schedule prevents estradiol troughs that can trigger hot flash recurrence. With transdermal gel, applying at the same time daily and to consistent locations supports stable levels.

Medical Disclaimer

The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

FDA Drug Database MedlinePlus (NIH) Cochrane Reviews How we rate evidence

Routes of Administration

Clinical profiles, VTE risk, and formulation distinctions by route

Oral tablets

VTE risk: high

Brands: Estrace · generic estradiol

Clot risk: Significantly higher VTE (blood clot) risk vs. transdermal. Oral estradiol undergoes first-pass liver metabolism, which activates hepatic clotting factors including Factor VII and fibrinogen.
Absorption: Full systemic — undergoes significant first-pass liver metabolism
Convenient once-daily dosing. Liver first-pass increases triglycerides, clotting factors, and SHBG. Current guidelines generally prefer transdermal in women with elevated clot risk, obesity, smoking history, or migraines with aura.

Transdermal patch

VTE risk: low

Brands: Vivelle-Dot · Climara · Alora · Minivelle

Clot risk: Substantially lower VTE risk than oral — bypasses liver first-pass metabolism, avoiding activation of hepatic clotting factors. Multiple observational studies (including the E3N cohort) confirm this distinction.
Absorption: Full systemic — bypasses first-pass liver metabolism via skin absorption
Applied 1–2× per week. Guideline-preferred route for women with VTE risk factors, obesity, or liver disease. Provides more stable estradiol blood levels than cyclic oral dosing. Adhesive skin reactions occur in ~10%; rotating sites helps.

Transdermal gel

VTE risk: low

Brands: Divigel · EstroGel · Elestrin

Clot risk: Similar to the patch — bypasses first-pass liver metabolism. Observational data show VTE risk comparable to transdermal patch and substantially lower than oral estradiol.
Absorption: Full systemic — bypasses first-pass liver metabolism via skin absorption
Applied daily to arm or thigh. Avoids adhesive issues common with patches. Alcohol-based gel dries quickly. Important: risk of transfer to others via skin contact if not fully dried. French guidelines specifically recommend transdermal estradiol (patch or gel) over oral.

Vaginal / local-only

VTE risk: minimal

Brands: Vagifem · Yuvafem (tablet) · Imvexxy (insert) · Estrace cream · Estring (ring)

Clot risk: Minimal systemic absorption at standard doses — negligible VTE risk. Does not provide systemic benefits (bone density, vasomotor symptoms, cardiovascular protection).
Absorption: Minimal systemic absorption at standard therapeutic doses
For genitourinary syndrome only (vaginal dryness, dyspareunia, recurrent UTIs). Does not typically require a progestogen for endometrial protection due to minimal systemic absorption. Can be continued even after systemic HRT is stopped. Often underused by patients who fear systemic HRT risks — the risk profile of local vaginal estrogen is very different.

Common Side Effects

While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.

Breast tenderness / fullness

20-30%

Often improves after the first 1-3 months as the body adjusts; dose reduction may help if persistent

Nausea

10%

More common with oral estradiol than transdermal; take oral form with food; transdermal avoids first-pass GI absorption

Headache / migraine

10%

Often related to hormone level fluctuations; transdermal delivery provides more stable levels than cyclic oral dosing

Bloating / water retention

8%

Usually improves after 2-3 months; reducing sodium intake may help

Mood changes / irritability

7%

Progesterone component (if combined therapy) is often the culprit; discuss formulation with your doctor

Vaginal spotting or bleeding

5-15%

Common in the first months; any unexpected bleeding after menopause should always be evaluated

Skin reaction at patch site

10%

Rotate patch sites; some patients switch to gel formulations to avoid adhesive reactions

Increased libido

Variable

Frequently reported as beneficial, particularly at lower physiological doses

Serious Adverse Effects

  • • Blood clots (DVT/PE) — risk is largely associated with oral estrogens; transdermal estradiol appears to carry substantially lower clot risk
  • • Stroke — risk elevated with higher oral doses; timing of initiation relative to menopause matters
  • • Endometrial cancer — risk significantly increased without concurrent progestogen in women with a uterus
  • • Breast cancer — relationship is complex; duration, timing, type, and combined use with progestogens all influence risk
  • • Gallbladder disease — oral estrogens increase gallstone risk; transdermal does not appear to

Drug Interactions

Major Interactions (Avoid)

TamoxifenEstradiol may reduce tamoxifen's effectiveness in breast cancer treatment — generally contraindicated together
Aromatase inhibitors (anastrozole, letrozole)Directly opposes their mechanism — contraindicated in hormone-receptor positive breast cancer

Moderate Interactions (Caution)

Thyroid hormone (levothyroxine)Estrogen increases thyroid-binding globulin; thyroid dose may need adjustment when starting or stopping estradiol
WarfarinEstrogen may enhance anticoagulant effect — monitor INR more frequently
Antiepileptics (carbamazepine, phenytoin)May accelerate estradiol metabolism, reducing effectiveness

Food Interactions

AlcoholIncreases estradiol blood levels and may increase breast cancer risk with long-term use
Grapefruit juiceMay increase estradiol levels by inhibiting liver metabolism

When to Contact Your Doctor

This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.

Contact soon if you notice

  • Blood clots (DVT/PE) — risk is largely associated with oral estrogens; transdermal estradiol appears to carry substantially lower clot risk
  • Stroke — risk elevated with higher oral doses; timing of initiation relative to menopause matters
  • Endometrial cancer — risk significantly increased without concurrent progestogen in women with a uterus
  • Breast cancer — relationship is complex; duration, timing, type, and combined use with progestogens all influence risk
  • Return of frequent or severe hot flashes disrupting sleep

Also discuss if you want to

  • Review whether this medication is still appropriate for you
  • Consider dosage adjustments based on response
  • Explore lifestyle or non-drug alternatives
  • Understand stopping or tapering options
  • Plan monitoring labs and follow-up

In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.

Special Populations

Safety classifications for specific groups — discuss with your provider before use.

ContraindicatedPregnancy

Estrogen is contraindicated in pregnancy. Stop immediately if pregnancy occurs or is suspected.

CautionBreastfeeding

Estradiol passes into breast milk and may reduce milk production. Discuss with your provider if breastfeeding.

The Primary IndicationMenopause / Hormonal

Vasomotor symptoms (hot flashes, night sweats), genitourinary changes, sleep disruption, mood shifts, and cognitive fog are all recognized menopausal manifestations that estradiol may address. The NAMS (North American Menopause Society) recommends hormone therapy as the most effective treatment for bothersome menopausal symptoms in healthy women under 60 or within 10 years of menopause.

Timing Matters SignificantlyOlder Adults

The "timing hypothesis" (ELITE trial) suggests estradiol initiated within 6-10 years of menopause — or before age 60 — may have cardiovascular benefit. Initiated 10+ years post-menopause, the risk-benefit profile shifts. Age at menopause and time since menopause are key factors in the shared decision.

Avoid Oral FormLiver Disease

Oral estradiol undergoes significant first-pass liver metabolism. Liver disease increases risk of side effects and clots. Transdermal estradiol largely bypasses liver metabolism and may be safer.

FDA Adverse Event Reports

Patient-filed reports from the FDA FAERS database · refreshed daily

Anecdotal data. Reports are not confirmed causation. Always consult your provider.

Community Reports

User-reported experiences — anonymous & anecdotal

Medical Disclaimer

The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

FDA Drug Database MedlinePlus (NIH) Cochrane Reviews How we rate evidence

Metabolic & Lifestyle Alternatives

Non-Hormonal Approaches for Menopausal Symptoms

A range of non-hormonal options have clinical evidence for menopausal symptoms. Effectiveness varies between individuals, and most have a narrower effect profile than estradiol. These are options to discuss with your provider — they may be appropriate alone, in combination, or as a bridge while considering hormone therapy.

Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.

Fezolinetant (Veoza)

Strong

FDA-approved 2023 non-hormonal option — neurokinin B receptor antagonist targeting the thermoregulatory pathway that causes hot flashes

Reduced moderate-to-severe hot flash frequency by ~60% in phase 3 trials; prescription required

Regular aerobic exercise

Consistent evidence that exercise reduces vasomotor symptom frequency and severity, and supports sleep and mood

Studies suggest 20-30% reduction in hot flash frequency; also improves bone density and cardiovascular health independently

Cognitive Behavioral Therapy (CBT)

CBT-based programs designed for menopause (e.g., Mindfulness-Based Stress Reduction) address hot flashes, sleep, and mood

Multiple RCTs show meaningful reduction in hot flash distress rating, even when frequency is unchanged

Magnesium glycinate (400mg at bedtime)

Supports sleep architecture and may reduce vasomotor symptoms through autonomic nervous system modulation

Observational and small trial data suggest improvement in sleep and mild hot flash reduction

How It Compares

Within Estrogens

Estradiol (17β-estradiol) is the bioidentical form of the body's primary estrogen, and is the preferred form in most current menopause specialist guidelines. It differs from conjugated equine estrogen (Premarin), which contains a mixture of estrogens derived from horse urine that are not naturally found in the human body.

Strengths

  • Bioidentical to the estrogen naturally produced by the ovaries
  • Transdermal delivery largely avoids liver first-pass — significantly lower clot risk than oral estrogens
  • Well-established efficacy for hot flashes, genitourinary symptoms, and bone density
  • Multiple delivery forms: patches, gels, sprays, rings, creams — allows personalized dosing
  • Generic transdermal options make it relatively affordable
  • Strong evidence base for cardiovascular protection when initiated within 10 years of menopause (timing hypothesis)

Weaknesses

  • Requires concurrent progesterone in women with an intact uterus (endometrial cancer risk without it)
  • Breast cancer risk with long-term use requires individualized monitoring and shared decision-making
  • Some women experience mood or bleeding changes — particularly with cyclic progesterone regimens
  • FDA black box warning can discourage prescribing, even when evidence supports its use in appropriate patients

Clinically Preferred Alternatives

Fezolinetant (Veoza)FDA-approved 2023 non-hormonal option for vasomotor symptoms — acts on the KNDy pathway in the hypothalamus. No hormonal exposure.
Low-dose vaginal estradiol (Vagifem, Imvexxy)For genitourinary syndrome of menopause only — very low systemic absorption; may not require concurrent progesterone.
SSRIs/SNRIs (paroxetine, venlafaxine)Non-hormonal; FDA-approved (paroxetine/Brisdelle) or commonly used off-label for hot flash frequency reduction.

Global Prescribing & Pricing

HRT use dropped sharply after the 2002 WHI publication and has only partially recovered; European countries maintain higher rates than the US

🇺🇸

United States

$30–80/mo

Rate

HRT use declined ~50% after 2002 WHI; slowly recovering as guidelines are revised

Policy

No national menopause policy; prescribing varies widely by provider training and specialty

Cover

Usually covered with prior authorization

🇬🇧

United Kingdom

~$5–15/mo

Rate

UK actively promotes HRT access; NHS menopause guidance revised in 2023 to improve access

Policy

UK introduced a fixed-fee HRT prescription certificate (£30.25/year) in 2023 to reduce cost barriers

Cover

Covered by NHS at subsidized rate

🇫🇷

France

~$5–20/mo

Rate

France has among the highest HRT use in Europe; bioidentical estradiol preferred over conjugated equine estrogen

Policy

French guidelines specifically recommend transdermal estradiol and bioidentical progesterone (Prometrium)

Cover

Covered by Sécurité Sociale

🇩🇪

Germany

~$10–25/mo

Rate

Moderate HRT use; shared decision-making emphasized between patient and gynecologist

Policy

S3 guidelines recommend individualized assessment; no blanket restrictions by age

Cover

Covered by GKV with prescription

🇦🇺

Australia

~$8–20/mo

Rate

TGA supports HRT access; estradiol available as subsidized PBS medicine

Policy

Australian Menopause Society actively advocates against blanket HRT avoidance based on outdated WHI interpretation

Cover

Subsidized via PBS

The 2002 WHI study — which used conjugated equine estrogen and synthetic progestins, not estradiol — caused a global decline in HRT prescribing that persisted for two decades. France's continued preference for transdermal estradiol and bioidentical progesterone, and the UK's 2023 prescription access reforms, reflect a re-evaluation that the US has been slower to adopt.

Clinical Trials & Funding

Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.

Funding Sources

The Women's Health Initiative was funded by the NIH/NHLBI — the largest independently funded women's health trial in US history. ELITE (Early vs Late Intervention Trial with Estradiol) was funded by the National Institute on Aging. KEEPS (Kronos Early Estrogen Prevention Study) received partial pharmaceutical funding (Abbott Labs supplied some study medications) alongside NIH support.

Declared Conflicts of Interest

The WHI did NOT study estradiol — it studied conjugated equine estrogen (Premarin) combined with medroxyprogesterone acetate (Provera). This distinction was underreported in media coverage. The compounding pharmacy industry has a financial interest in promoting bioidentical alternatives over FDA-approved transdermal estradiol, creating a different type of funding conflict. Wyeth/Pfizer (Premarin manufacturer) lost major market share following the WHI, influencing how follow-up research was framed and funded.

Key Efficacy Results

WHI used Premarin+Provera (not estradiol) — results may not apply directly to transdermal estradiol. ELITE found cardiovascular benefit when estradiol started within 6 years of menopause; no benefit when started 10+ years later.

Referenced Studies

Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.

WHI Combined HRT Arm (NIH)
ELITE Trial — Timing Hypothesis (NIA)
ELITE Results — NEJM 2016
KEEPS Trial

Evidence & Transparency

Cochrane RoB-2 (Risk of Bias)

Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗

CMS Open Payments

Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗

Live Clinical Trials

Live from ClinicalTrials.gov · refreshed every 4 hours

Currently enrolling, active, and recently completed studies involving Estradiol (17β-Estradiol). Data is pulled directly from the U.S. National Library of Medicine.

Recent Research

Live from PubMed · peer-reviewed literature · refreshed every 4 hours

Most recently indexed clinical trials and systematic reviews mentioning Estradiol (17β-Estradiol) in PubMed.

Source Documentation

Structured citations for referenced clinical trials

Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.

TrialRegistry IDCite
WHI Combined HRT Arm (NIH)NCT00000611
ELITE Trial — Timing Hypothesis (NIA)NCT00114517
ELITE Results — NEJM 2016PMID:26046137
KEEPS TrialNCT00154180

Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.

Our Methodology

Medical Disclaimer

The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

FDA Drug Database MedlinePlus (NIH) Cochrane Reviews How we rate evidence

Stopping This Medication Safely

Taper GraduallyDocumented timeframe: 3–6 months recommended; faster if medically necessary with provider guidance

Abrupt estradiol discontinuation typically causes a return of vasomotor symptoms — often transiently more intense than the original symptoms before the body re-equilibrates. Gradual tapering over several months allows a smoother transition and helps distinguish true menopausal symptom recurrence from withdrawal.

What Published Research Shows About Stopping This Medication

This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.

  • ·Research documents that timing of discontinuation relative to age and menopause stage affects outcomes — specialist guidance is supported by evidence
  • ·Published protocols describe reducing patch dose by one step (e.g., 0.1 → 0.075 → 0.05 → 0.025 mg/day) over 3-6 months
  • ·For oral estradiol, published approaches describe reduction by 0.5mg decrements every 4-8 weeks
  • ·Research supports non-hormonal strategies (exercise, CBT, magnesium) as useful preparation before reducing dose

Warning Symptoms — Contact Your Doctor If You Experience:

  • Return of frequent or severe hot flashes disrupting sleep
  • Significant mood deterioration or anxiety
  • Vaginal dryness or discomfort affecting daily life
  • Bone pain or rapid loss of bone density on DEXA scan

Never change or stop a medication without consulting your prescribing physician.

Questions for Your Doctor

Questions to Ask

  • 1.Are we using transdermal estradiol (patch or gel) rather than oral — and if not, why?
  • 2.Do I need a progestogen with estradiol, and if so, which one — bioidentical progesterone or a synthetic progestin?
  • 3.How does the timing of when I started menopause affect my risk-benefit calculation?
  • 4.What is the plan for monitoring — when will we reassess whether to continue?
  • 5.Are my symptoms definitely related to menopause, or could other causes be contributing?

Lab Tests to Request

  • Estradiol level (serum)
  • FSH level (to confirm menopause transition)
  • Thyroid panel (TSH)
  • Lipid panel and blood pressure
  • Bone density (DEXA) if osteoporosis risk is a factor
  • Mammogram (per screening schedule)
  • Endometrial assessment if indicated

Medical Disclaimer

The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

FDA Drug Database MedlinePlus (NIH) Cochrane Reviews How we rate evidence

Frequently Asked Questions About Vivelle-Dot® / Climara® / Estrace®

What is Vivelle-Dot® / Climara® / Estrace® used for?
Vivelle-Dot® / Climara® / Estrace® (Estradiol (17β-Estradiol)) is a Estrogen / Sex Hormone manufactured by Bayer (Climara) / Various Generic. FDA-approved indications include: Menopausal vasomotor symptoms (hot flashes, night sweats); Genitourinary syndrome of menopause; Osteoporosis prevention post-menopause; Hypogonadism; Gender-affirming therapy.
What are the common side effects of Vivelle-Dot® / Climara® / Estrace®?
Common side effects of Vivelle-Dot® / Climara® / Estrace® include: Breast tenderness / fullness (20-30%); Nausea (10%); Headache / migraine (10%); Bloating / water retention (8%); Mood changes / irritability (7%).
How much does Vivelle-Dot® / Climara® / Estrace® cost?
Vivelle-Dot® / Climara® / Estrace® list price is approximately $120. With insurance it typically costs $10-30; without insurance approximately $30-80.
Who funded the clinical trials for Vivelle-Dot® / Climara® / Estrace®?
The Women's Health Initiative was funded by the NIH/NHLBI — the largest independently funded women's health trial in US history. ELITE (Early vs Late Intervention Trial with Estradiol) was funded by the National Institute on Aging. KEEPS (Kronos Early Estrogen Prevention Study) received partial pharmaceutical funding (Abbott Labs supplied some study medications) alongside NIH support.
How strong is the clinical evidence for Vivelle-Dot® / Climara® / Estrace®?
Key studies: WHI (Estrogen-Alone & Combined Arms), ELITE Trial, KEEPS Trial, MWS (UK). WHI used Premarin+Provera (not estradiol) — results may not apply directly to transdermal estradiol. ELITE found cardiovascular benefit when estradiol started within 6 years of menopause; no benefit when started 10+ years later. Potential conflicts of interest: The WHI did NOT study estradiol — it studied conjugated equine estrogen (Premarin) combined with medroxyprogesterone acetate (Provera). This distinction was underreported in media coverage. The compou.
Are there non-drug alternatives to Vivelle-Dot® / Climara® / Estrace®?
A range of non-hormonal options have clinical evidence for menopausal symptoms. Effectiveness varies between individuals, and most have a narrower effect profile than estradiol. These are options to discuss with your provider — they may be appropriate alone, in combination, or as a bridge while cons See the Alternatives tab for full details.

Get notified when we update Vivelle-Dot® / Climara® / Estrace®

We'll email you when new evidence, safety updates, or alternatives are added.

No spam. Unsubscribe anytime.